This filing is purely administrative with no trading implications. Monitor future 6-K filings for any material business developments such as pipeline updates, partnership changes, or financial results.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $25.39entry
- T+1 · 5mo ago −0.47%α −1.25% · $25.27
- T+5 · 5mo ago +1.87%α +2.91% · $25.87
- T+20 · 4mo ago +14.14%α +12.82% · $28.98
- T+60 · 2mo ago +27.89%α +24.74% · $32.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab filed its updated Articles of Association (June 16, 2026) via a 6-K on June 17, 2026. The document is a routine corporate governance update covering standard provisions on share capital, warrant programs, board composition, and meeting procedures. No material financial, operational, or strategic changes were disclosed.
Key Facts
- Share capital remains DKK 62,353,252 divided into shares of DKK 1 each.
- Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 with or without pre-emption rights.
- Multiple warrant programs for employees (excluding executive management) with caps of DKK 750,000 each under various general meeting authorizations.
- Convertible debt instrument authorization up to DKK 3,000,000 nominal value until March 12, 2029.
- Indemnification scheme for board members established through March 12, 2029.
- Group language set to English; annual reports in English (and optionally Danish).
Financial Impact
No financial impact; routine governance filing with no new financial data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000097 |
| Document: gmab_20260617x6k.htm | 0001434265-26-000097 |
| Document: 0001434265-26-000097-index-headers.html | 0001434265-26-000097 |
| Document: 0001434265-26-000097-index.html | 0001434265-26-000097 |
| Document: 0001434265-26-000097.txt | 0001434265-26-000097 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers